Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. (NASDAQ: ACON) is a commercial-stage healthcare technology company focused on chronic low back pain, using Magnetic Resonance Spectroscopy (MRS), biomarkers, and augmented intelligence (AI) algorithms to help physicians identify which lumbar discs may be sources of pain. This news page aggregates updates and announcements related to Aclarion’s business, technology, and clinical programs.
Readers can find coverage of Nociscan, Aclarion’s evidence-supported SaaS platform that noninvasively helps distinguish between painful and nonpainful discs in the lumbar spine. News items often highlight scan volume trends across U.S., U.K., and E.U. sites, payer coverage developments such as private insurer reimbursement in the U.K., and the addition of new imaging centers and physician users. These updates provide context on how Nociscan is being adopted in clinical practice.
A key theme in ACON news is clinical evidence generation. Articles describe the pivotal CLARITY trial, a multi-site randomized study evaluating whether incorporating Nociscan into surgical planning can improve outcomes for patients undergoing surgery for chronic low back pain. Other news discusses real-world evidence publications, including cost-effectiveness analyses and case studies published in journals like the International Journal of Spine Surgery, as well as presentations at scientific meetings such as the International Society of Pain and Neuroscience (ISPN).
Financial and corporate developments also feature prominently. Press releases cover equity financings, cash runway updates, and the company’s debt-free balance sheet, along with leadership appointments in finance and commercial roles. Together, these news items offer investors, clinicians, and other stakeholders a consolidated view of Aclarion’s progress in technology development, market expansion, and clinical validation. Users interested in ACON can monitor this page for ongoing announcements related to Nociscan, CLARITY, payer engagement, and broader corporate milestones.
Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology firm, is set to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference from February 21-24, 2023. Jeff Thramann, Executive Chairman, will present on February 21 at 11:30 AM ET. The conference will feature 37 top companies selected by qualified institutional investors. Aclarion leverages biomarkers and augmented intelligence to identify chronic low back pain and has developed Nociscan, a SaaS platform that helps physicians distinguish between painful and nonpainful discs. For more details, visit www.aclarion.com.
Aclarion, a healthcare tech company focusing on chronic low back pain (CLBP), announced its participation in the 2nd Annual Sonntag Spine Symposium on February 17, 2023. Aclarion's flagship product, Nociscan, is the first SaaS platform that objectively measures discogenic biomarkers to aid in diagnosing CLBP. This innovative tool helps distinguish between painful and nonpainful discs, providing critical insights for treatment strategies. With over 266 million people affected by generative spine disease globally, Nociscan aims to optimize clinical outcomes through enhanced decision support for physicians.
Aclarion, a healthcare technology company listed on Nasdaq under ACON and ACONW, has appointed Dr. Gregory Basil from the University of Miami as a key opinion leader. Dr. Basil, a renowned spine surgeon, aims to enhance clinical outcomes through Aclarion's innovative Nociscan platform, which identifies chronic low back pain sources via biomarkers. This SaaS solution allows physicians to differentiate between painful and nonpainful lumbar discs, offering critical insights for optimized treatment strategies. Dr. Basil is the seventh advisor to join Aclarion's clinical evidence team, reinforcing its commitment to improving patient care.
Aclarion, Inc. (Nasdaq: ACON, ACONW) has appointed George Frey, MD, as a key opinion leader to guide its innovative Nociscan solution for chronic low back pain (cLBP). Dr. Frey, founder of the Colorado Comprehensive Spine Institute, has extensive experience in medical device invention and patents. Aclarion's Nociscan platform uses biomarkers and algorithms to identify painful lumbar discs, addressing a major healthcare challenge. As cLBP significantly contributes to opioid addiction and healthcare costs, the company's advancements offer a new approach. Aclarion aims to leverage Dr. Frey's expertise to enhance its strategy and expand its KOL program into 2023.
Aclarion, a healthcare technology company, has appointed Dr. Christopher Ames as a Key Opinion Leader to enhance its Nociscan solution for chronic low back pain (cLBP). This SaaS platform is the first evidence-supported tool that helps physicians differentiate between painful and nonpainful discs in the lumbar spine. Dr. Ames emphasizes that the Nociscan tool will improve diagnostic clarity and patient outcomes. Additionally, Aclarion's Nociscan is included in a pivotal NIH-funded trial and has recently secured a new patent addressing painful disc degeneration.
Aclarion, a healthcare technology company, has appointed Dr. Eric Potts as a key opinion leader. Dr. Potts, a neurosurgeon, will assist in promoting Aclarion's Nociscan solution, which helps physicians identify chronic low back pain. Nociscan is the first SaaS platform to noninvasively distinguish between painful and nonpainful discs, leveraging chemical biomarkers. Aclarion aims to strengthen its clinical evidence and market support for this innovative approach, enhancing treatment strategies while addressing a major healthcare issue.
Aclarion, Inc. (ACON, ACONW) announced the appointment of Dr. Juan Uribe as a key opinion leader to enhance its efforts in chronic low back pain (cLBP) diagnostics. Dr. Uribe, renowned in spinal disorder research, will support Aclarion's objective of integrating clinical evidence and securing payer advocacy. The company's flagship Nociscan platform noninvasively identifies painful versus nonpainful lumbar discs using advanced biomarkers and algorithms. Aclarion aims to improve diagnostic accuracy and treatment strategies for cLBP, a leading cause of opioid addiction in the U.S.
Aclarion, Inc. (Nasdaq: ACON) has received a Notice of Allowance for its US Patent Application 16/224,590, enhancing its patent portfolio to 22 U.S. patents. This patent allows Aclarion to utilize Magnetic Resonance Spectroscopy (MRS) to identify Propionic Acid, a biomarker linked to bacterial infections in intervertebral discs. The Nociscan platform aids physicians in distinguishing between painful and nonpainful discs, potentially reducing unnecessary surgeries. CEO Brent Ness emphasized the importance of this advancement in supporting optimal treatment decisions for chronic low back pain.
Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology company, presented at the 15th annual LD Micro Main Event on October 25, 2022. Executive Chairman Jeff Thramann delivered a company overview and business update. Aclarion focuses on chronic low back pain through its Nociscan platform, utilizing biomarkers and augmented intelligence to aid physicians in identifying pain sources in the lumbar spine. An updated investor presentation is available on their website, enhancing investor communications.
Aclarion, a healthcare technology company, has announced that Dr. Sigurd Berven will join as a key opinion leader to enhance the company's efforts in chronic low back pain diagnosis. Aclarion's Nociscan platform uniquely identifies painful discs using biomarkers and augmented intelligence. This technology aims to improve diagnostic accuracy and treatment strategies. Recently included in a NIH-funded trial, Nociscan further establishes its significance in the spine industry. Aclarion's focus is on robust clinical evidence and payer engagement to drive the adoption of its innovative solutions.
FAQ
What is the current stock price of Aclarion (ACON)?
What is the market cap of Aclarion (ACON)?
